Get the Stockscreener App
72.37
0.51%
+0.37
Intra-Cellular Therapies Inc stock is currently priced at $72.37, with a 24-hour trading volume of 2.10M.
It has seen a +0.51% increased in the last 24 hours and a +10.57% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $72.76 pivot point. If it approaches the $70.44 support level, significant changes may occur.
Intra-Cellular Therapies Inc Stock (ITCI) Financials Data
Intra-Cellular Therapies Inc (ITCI) Revenue 2024
ITCI reported a revenue (TTM) of $462.18 million for the quarter ending December 31, 2023, a +85.51% rise year-over-year.
Intra-Cellular Therapies Inc (ITCI) Net Income 2024
ITCI net income (TTM) was -$139.67 million for the quarter ending December 31, 2023, a +45.49% increase year-over-year.
Intra-Cellular Therapies Inc (ITCI) Cash Flow 2024
ITCI recorded a free cash flow (TTM) of -$124.47 million for the quarter ending December 31, 2023, a +54.06% increase year-over-year.
Intra-Cellular Therapies Inc (ITCI) Earnings per Share 2024
ITCI earnings per share (TTM) was -$1.46 for the quarter ending December 31, 2023, a +46.32% growth year-over-year.
Intra-Cellular Therapies Inc Stock (ITCI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mates Sharon | Chairman, President & CEO |
Mar 11 '24 |
Sale |
65.21 |
20,565 |
1,341,123 |
1,050,309 |
| Hineline Lawrence J. | SVP of Finance, CFO |
Mar 11 '24 |
Sale |
65.96 |
10,121 |
667,587 |
0 |
| Halstead Michael | EVP and General Counsel |
Mar 11 '24 |
Sale |
65.97 |
7,345 |
484,537 |
0 |
| Neumann Mark | EVP, Chief Commercial Officer |
Mar 11 '24 |
Sale |
65.61 |
7,345 |
481,931 |
29,700 |
| Durgam Suresh K. | EVP, Chief Medical Officer |
Mar 11 '24 |
Sale |
65.59 |
3,712 |
243,482 |
19,803 |
| Hineline Lawrence J. | SVP of Finance, CFO |
Mar 10 '24 |
Option Exercise |
56.73 |
4,539 |
257,497 |
4,539 |
| Mates Sharon | Chairman, President & CEO |
Mar 07 '24 |
Sale |
66.50 |
40,712 |
2,707,277 |
1,050,309 |
| Hineline Lawrence J. | SVP of Finance, CFO |
Mar 07 '24 |
Sale |
66.60 |
13,132 |
874,560 |
0 |
| Neumann Mark | EVP, Chief Commercial Officer |
Mar 07 '24 |
Sale |
66.57 |
13,132 |
874,179 |
29,700 |
| Halstead Michael | EVP and General Counsel |
Mar 07 '24 |
Sale |
66.15 |
13,132 |
868,698 |
0 |
Intra-Cellular Therapies Inc Stock (ITCI) Latest News
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
Zacks Investment Research
Intra-Cellular Therapies Prices Public Offering of Common Stock
GlobeNewswire Inc.
Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals
Zacks Investment Research
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
Zacks Investment Research
Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday
Benzinga
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
GlobeNewswire Inc.
About Intra-Cellular Therapies Inc
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. It is also developing ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
COMPANY PROFILE
NameIntra-Cellular Therapies Inc
SectorHealthcare (1201)
Industry
Web
Phone646-440-9333
Employee49
SEC filings
Latest SEC Filings
Next earning date2024-05-02
Address430 East 29th Street, Suite 900, New York, NY, United States (10016)
4.57%
0.32%
Cap:
|
Volume (24h):